Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARERE: Panitumumab Rechallenge Followed by Regorafenib Versus the Reverse Sequence in mCRC
NCT04787341Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Dec 2020
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab, regorafenib in colorectal cancer (CRC), sponsored by Gruppo Oncologico Nord Ovest. Started Dec 2020; status: completed.
02
Drugs
panitumumabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04787341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787341.